Equities analysts expect that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will post earnings of ($0.27) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with estimates ranging from ($0.35) to ($0.18). Adaptimmune Therapeutics reported earnings of ($0.29) per share in the same quarter last year, which would suggest a positive year over year growth rate of 6.9%. The business is scheduled to issue its next quarterly earnings report on Thursday, March 21st.
On average, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.21) to ($0.84). For the next fiscal year, analysts forecast that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.50) to ($0.94). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.09. The business had revenue of $40.79 million during the quarter, compared to analysts’ expectations of $29.41 million. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 46.63%.
NASDAQ:ADAP traded down $0.48 during trading hours on Friday, reaching $6.18. The company had a trading volume of 682,729 shares, compared to its average volume of 523,246. The stock has a market capitalization of $616.54 million, a price-to-earnings ratio of -7.73 and a beta of 2.02. Adaptimmune Therapeutics has a twelve month low of $5.73 and a twelve month high of $14.63.
In related news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $13.79, for a total transaction of $344,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ali Behbahani purchased 12,000,000 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were purchased at an average cost of $1.67 per share, for a total transaction of $20,040,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. lifted its position in shares of Adaptimmune Therapeutics by 18.2% during the second quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares in the last quarter. BlackRock Inc. lifted its position in shares of Adaptimmune Therapeutics by 2.5% during the first quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock valued at $9,062,000 after purchasing an additional 19,765 shares in the last quarter. Frontier Capital Management Co. LLC raised its position in Adaptimmune Therapeutics by 351.1% in the third quarter. Frontier Capital Management Co. LLC now owns 698,694 shares of the biotechnology company’s stock worth $9,474,000 after acquiring an additional 543,809 shares during the period. Stanley Laman Group Ltd. bought a new stake in Adaptimmune Therapeutics in the third quarter worth about $7,665,000. Finally, JPMorgan Chase & Co. raised its position in Adaptimmune Therapeutics by 786.0% in the first quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after acquiring an additional 164,704 shares during the period. 58.99% of the stock is currently owned by institutional investors.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.